Patient Experience Data Archives

Research Points to Inconsistent Use of Patient Experience Data in FDA Approvals

21st Century Cures Act, Approvals, Biologics, Biologics License Application (BLA), FDA, New Drug Applications, Orphan Drug Designation, Patient Experience Data, Researchers

Sanofi is pressing the U.S. Food and Drug Administration to keep the company’s patient experience data consistent following a review of approved applications required by the 21st Century Cures Act.

October 15, 2019/by BioSpace